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Introduction
Heparin is the most commonly prescribed anticoagulant 
for use during continuous renal replacement therapy 
(CRRT) [1]. By implication, it is considered the standard of 
care. Th  ere is, however, increasing evidence question  ing 
the safety of heparin particularly in the critically ill, and 
there are accumulating data on a potential better 
alternative, regional anticoagulation with citrate. In the 
present review, we discuss some of the complex inter-
actions between heparin and the coagulation and inﬂ  am-
mation pathways, the associated consequences of such 
interactions in terms of eﬃ   cacy and safety in the critically 
ill, and the availability of the promising alternative citrate.
Heparin
In the present manuscript we often refer to heparin, not 
discriminating between unfractionated heparin and low 
molecular weight heparin (LMWH). Clinicians should, 
however, be aware of their diﬀ  erences [2]. LMWHs have 
a lower antithrombin (AT) dependency, cause less tissue 
plasminogen activator inhibitor depletion, exhibit less 
binding to proteins and cells, cause less activation of 
platelet factor 4 and cause less heparin-induced thrombo-
cytopenia. Some of the eﬀ   ects mentioned below will 
therefore be less pronounced for LMWH. Many of these 
eﬀ  ects are, however, described for LMWH as well – in 
such cases, we have indicated this in the text or the tables.
Heparin resistance
Low antithrombin due to consumption and inactivation
Th  e anticoagulant eﬀ  ect of heparins depends on poten-
tiating AT, the most important endogenous inhibitor of 
thrombin and other coagulation factors [2]. In critically 
ill patients, however, AT concentrations are often 
reduced as a result of consumption due to activation of 
coagulation in conditions such as sepsis or systemic 
inﬂ  ammation. AT is also reduced as a result of proteolytic 
degradation by granulocyte-derived elastase, and this 
eﬀ   ect is actually enhanced by heparin [3,4]. During 
inﬂ  am  mation, elastase release is increased while its in-
activation is decreased, because oxygen radicals decrease 
the activity of its natural inactivator α1-antitrypsin. Both 
high AT consumption and increased AT degradation thus 
contribute to heparin resistance during critical illness.
Critical illness-induced heparin binding
Heparins not only bind to AT, but additionally to numer  ous 
other proteins and cells, thereby inducing unpredic  table 
eﬀ  ects on many body functions. Th   e bind  ing of heparin 
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available to act as a cofactor for AT and thus decreases its 
anticoagulant eﬀ   ect [5]. So-called heparin-binding 
proteins are released from endothelial stores [6]. Among 
these are acute-phase reactants such as platelet factor 4, 
histidine-rich glycoprotein, vitronectin, ﬁ   bro nec tin  and 
lipopolysaccharide-binding protein, all of which increase 
in sepsis and other forms of inﬂ  ammation  [2,7-9]. 
Furthermore, heparin avidly binds to apoptotic and 
necrotic cells to discrete domains released from the 
nucleus onto the membrane as the cell dies [10]. Aﬃ   nity 
of dead cells decreases if heparins with a lower molecular 
weight are used. Apoptosis is a key mechanism of cell 
injury in sepsis-related multiorgan failure, while necrotic 
cells are abundant in ischemia reperfusion injury. 
Importantly, the heparin-binding sites on apoptotic cells 
also signal phagocytotic clearance, and thus heparin may 
actually delay such clearance [10].
A recent study in critically ill patients with acute kidney 
injury receiving CRRT with LMWH anticoagulation 
(nadro  parin) found that early ﬁ  lter clotting was asso  cia  ted 
with severe organ failure, consumptive coagulopathy and 
heparin resistance. LMWH resistance was inde  pendent of 
low AT levels [11]. In addition to low AT levels, increased 
heparin binding is therefore a feature of critical illness, also 
with the use of LMWH, and contri  butes to heparin 
resistance and possibly to other deleterious eﬀ  ects such as 
delayed phagocytotic removal of dead cells [10].
Heparin and bleeding
Th  e main drawback of heparin is that it causes systemic 
anticoagulation in addition to circuit anticoagulation. 
Heparin thus increases the patient’s risk of bleeding. 
Critically ill patients are at risk of bleeding due to recent 
surgery, trauma, mucosal lesions and coagulopathy. More 
or less severe bleeding events are reported in 10 to 50% of 
cases, depending on the population and the degree of anti-
coagulation [12,13]. Using no anticoagulation treatment is 
a safe option with regard to bleeding, but not to clotting, 
because the circuit life is generally reduced. Circuit anti-
coagu  lation without systemic anticoagulation (for example, 
regional anticoagulation) represents an ideal solution. 
Antagonizing heparin by administering prota  mine after 
the ﬁ  lter confers regional anticoagu  lation. Th  e  circulating 
heparin–protamine complexes, however, may be harmful 
[14]. Regional anticoagulation with sodium citrate seems 
an attractive alternative. Th   is topic is dis  cussed below.
Heparins and infl  ammation
Proinfl  ammatory eff  ects: antithrombin mediated
Binding of heparin to AT not only potentiates its anti-
coagulant eﬀ  ects, but additionally inhibits the anti-inﬂ  am-
matory actions of AT. Th  e anti-inﬂ  ammatory eﬀ  ects of 
AT are exerted through binding to gluco  s  amino  glycans 
on endothelial membranes, enhancing the formation of 
prostacyclin. Th  e binding of AT to glucos  amino  glycans   
diminishes the adherence and migration of leukocytes, 
reduces platelet aggregation and decreases proinﬂ  am-
matory cytokine production [15,16]. Heparin binding to 
AT abolishes this eﬀ  ect [15]. Further  more, during sepsis 
or ischemia reperfusion, elastase is increased. Recent data 
indicate that heparin, which normally poten  tiates AT, 
inactivates AT in the presence of elastase. Th  is process 
leads to proinﬂ  am  matory and procoagulant eﬀ  ects on the 
endothelium in sepsis, which may com  pro  mise the 
microcirculation and threaten tissue perfusion [4]. 
Heparin may thus have adverse eﬀ  ects on the micro-
circulation in sepsis [17,18].
Proinfl  ammatory and anti-infl  ammatory eff  ects not related 
to antithrombin
Both unfractionated heparin and LMWH can mobilize 
inﬂ   ammatory mediators – such as myeloperoxidase, 
lactoferrin, elastase and platelet factor 4 – not only from 
circulating neutrophils and platelets and from cells 
adhered to and activated by the dialysis membrane, but 
also from glucosaminoglycans such as heparan sulfate on 
the endothelial surface [19-21]. Although this release 
may be interpreted as being protective for the endothe-
lium, LMWH dialysis has been associated with higher 
serum concentrations of oxidized low-density lipopro-
teins com  pared with citrate dialysis, possibly indicating 
systemic oxidizing eﬀ  ects by myeloperoxidase [20].
Mobilization of inﬂ   ammatory mediators from endo-
thelial glucosaminoglycans may be especially relevant in 
sepsis and other forms of inﬂ   ammation. Heparin also 
releases the protective superoxide dismutase from the 
endothelium [22] and may have other anti-inﬂ  ammatory 
properties as well [23]. Th  ese  anti-inﬂ  ammatory proper-
ties may be partially mediated by inhibiting thrombin 
generation [24]. In addition, heparin – at much higher 
doses than used for anticoagulation – seems to attenuate 
endothelial dysfunction after ischemia–reperfusion injury 
by blocking the inﬂ  ammatory cascade at multiple levels, 
including complement activation [25], P-selectin and 
L-selectin-initiated cell adhesion and inﬂ  ux, and activa-
tion of the proinﬂ  ammatory transcription factor NF-κB 
[26,27]. In contrast to the observations in plasma-free 
conditions, where heparin seems to reduce endotoxin-
induced cytokine synthesis dose dependently [9] and to 
bind TNF [23,28], both unfractionated heparin and 
LMWH cause a dose-dependent increase in IL-8 and 
IL-1β in plasma, which depends on the presence of 
lipopolysaccharide-binding protein [9]. Heparin binds to 
lipopolysaccharide-binding protein, and this binding 
facilitates the transfer of lipopolysaccharide to the CD14 
receptor, thereby augmenting the endotoxin-induced 
activation of monocytes [9,18]. It should be noted that, 
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circuit, higher doses of heparins are often required, 
increasing the risk of proinﬂ  ammatory eﬀ  ects [9,29].
Altogether, translation of these experimental results to 
critically ill patients remains speculative. Post hoc analysis 
of the major sepsis trials in humans suggests that low-
dose heparin might have favorable eﬀ   ects on survival 
[23]. Th  ere is, however, probably a bias – the patients 
receiving heparin were less critically ill compared with 
those judged unable to tolerate heparin. Altogether, due 
to its avid binding properties, both unfractionated 
heparin and LMWH interfere at multiple levels with the 
inﬂ  ammatory cascade (Figure 1). Th  e  eﬀ  ects depend on 
the dose, timing, the clinical setting and many unknown 
factors, leading to unpredictable eﬀ  ects.
Heparin-induced thrombocytopenia
A feared side eﬀ   ect of heparins is the development of 
heparin-induced thrombocytopenia, related to the bind  ing 
of heparin to platelet factor 4 released from activated 
platelets. Some patients develop antibodies against this 
heparin–platelet factor 4 complex. Th  e  antibody–platelet 
factor 4–heparin complex subse  quently binds to 
platelets, inducing platelet activation, aggregation and 
activation of the coagulation pathways. Th  is sequence 
results in a loss of circulating platelets and a 
prothrombotic state [30]. Depending on the dose and 
type of heparin, on the population and on the criteria 
used for diagnosis, <1 to 5% of heparin-treated patients 
develop heparin-induced thrombocytopenia [31-33].
Citrate
Given the above concerns with heparin, why is regional 
citrate anticoagulation not the standard of care? For several 
reasons, physicians are reluctant to switch to citrate 
anticoagulation. Th  ese reasons include concerns that the 
use of citrate is complex, carries a high risk of metabolic 
derangement, might even be dangerous and is expensive.
Figure 1. Simplifi  cation of heparin binding to proteins and cells. Heparins bind to proteins and cells, and thereby interfere with the infl  ammatory 
cascade and, altogether, confer unpredictable consequences for critically ill patients. H, heparin; AT, antithrombin; LBP, lipopolysaccharide-binding 
protein; M, monocyte; MPO, myeloperoxidase; SOD, superoxide dismutase; GAGs, glucosaminoglycans; P, platelet; L, leukocyte.
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Citrate is both an anticoagulant and a buﬀ  er, and for this 
reason it can be diﬃ   cult to use and understand. Sodium 
citrate, administered before the ﬁ  lter, chelates calcium. 
Th   e associated regional hypocalcemia in the ﬁ  lter inhibits 
the generation of thrombin [34,35]. Citrate is partially 
removed by ﬁ  ltration or dialysis [36], and the remaining 
amount is rapidly metabolized in the citric acid (Krebs) 
cycle – especially in the liver, muscle and renal cortex – 
while the chelated calcium is released and the lost 
calcium is replaced. Systemic coagulation is unaﬀ  ected.
For anticoagulation, the citrate dose is adjusted to 
blood ﬂ  ow to attain an ionized calcium concentration 
<0.4 mmol/l in the ﬁ  lter; the lower the calcium concen-
tration, the higher the degree of anticoagulation. Some 
protocols use a ﬁ  xed dose of citrate in relation to blood 
ﬂ  ow according to an algorithm, and target such doses at 
about 3 mmol citrate/l blood ﬂ  ow [37]. Other protocols 
measure postﬁ  lter ionized calcium and adjust the citrate 
dose, which complicates the intervention but optimizes 
anti coagulation  [13,38].
While the anticoagulant strength of the citrate solution 
depends on the citrate concentration, the buﬀ  er strength 
depends on the proportion of strong cations in the ﬂ  uid 
counterbalancing the citrate anion. One micromole of 
trisodium citrate provides the same buﬀ  er as 3 mmol 
sodium bicarbonate, assuming the citrate is completely 
metabolized. In some solutions, however, hydrogen is 
used instead of sodium for some of the cation. Hydrogen 
(citric acid) does not act as a buﬀ  er. For example, in the 
ACD-A solution (citrate dextose) that is used in many 
protocols, 30% of the cations consist of hydrogen. Th  e 
buﬀ  ering capability of this solution is thus lower than 
when a pure trisodium citrate solution is used. In our 
view, the Stuart concept of acid–base provides an easier 
way to understand the buﬀ  ering eﬀ  ect of citrate for those 
familiar with the concepts. After metabolism of citrate, 
the remaining sodium increases the strong ion diﬀ  erence 
(SID) [39,40]:
SID = (Na+ + K+ + Ca2+ + Mg2+) – (Cl– + lactate–)
An increased SID produces alkalosis, while the infusion 
of a zero-SID ﬂ  uid decreases SID and causes acidosis. 
Citrate is a triprotic acid with pKa values of 3.13, 4.76 and 
6.40. A sodium citrate solution thus has a SID of zero 
until the citrate is metabolized. In conditions where 
citrate metabolism is grossly impaired, therefore, even 
trisodium citrate can ﬁ  rst cause some acidosis before it 
produces its alkalinizing eﬀ  ect.
Because sodium citrate acts as buﬀ  er, the replacement 
ﬂ  uids must be adjusted accordingly. A myriad of home-
made systems are in use and, unfortunately, add to 
confusion among clinicians: for predilution or 
post  dilution, for hemodialysis or hemoﬁ  ltration, or for 
their combination. All these modalities use diﬀ  erent 
ﬂ   uids and diﬀ   erent ways to attain metabolic stability. 
None of the systems has yet proven superiority. Th  e  pros 
and cons have been summarized in various reviews [38].
Metabolic consequences, tolerance and limitations
Reported derangements include metabolic alkalosis and 
acidosis, hypernatremia and hyponatremia, and hypo-
calcemia. Th   ey are detected with proper monitoring and 
the local protocol should describe how to adjust ﬂ  ows 
under diﬀ  erent conditions to prevent such prob  lems. Th  e 
incidence of metabolic complications depends on the 
amount of citrate administered, the design, rules and 
ﬂ   exibility of the protocol, and its proper use. In the 
largest randomized controlled trial, metabolic control 
with citrate was better than with heparin [35].
Calcium
Citrate tolerance depends on the amount of citrate enter-
ing the body and the capacity to metabolize citrate. Th  e 
amount of citrate needed for anticoagulation is lower 
when using continuous hemodialysis compared with 
hemo ﬁ  ltration, because dialysis can be performed at a 
lower blood ﬂ  ow and therefore requires a lower citrate 
dose. Citrate metabolism is diminished in case of liver 
failure and also of poor tissue perfusion [41,42], because 
the Krebs cycle only operates under aerobic conditions. 
Citrate accumulates if its metabolism is insuﬃ   cient. Th  e 
citrate molecule is not toxic in itself, but citrate 
accumulation causes ionized hypocalcemia in the 
systemic circulation, which may decrease cardiac 
contractility, cause hypo  tension by decreasing vascular 
tone and contribute to systemic hypocoagulability. 
Monitoring of the patient’s ionized calcium is therefore 
crucial. Ionized hypo  cal  cemia is the most sensitive 
indicator of citrate accumu  lation, but it can also stem 
from other causes, including an insuﬃ   cient replacement 
rate. Citrate accumulation, while decreasing ionized 
calcium, concomitantly increases the total calcium 
concentration, because the citrate-bound calcium 
increases and calcium is replaced. Th  e total to ionized 
calcium ratio, therefore, is a useful test to detect citrate 
accumulation [43-45]. A rise in total to ionized calcium 
ratio above 2.25 should trigger con  sideration of probable 
citrate accumulation [43]. Although citrate accumulation 
can also increase the anion gap, this variable is insensitive 
in critically ill patients. In the aforementioned 
randomized trial, citrate anticoagulation was better 
tolerated than heparin [37].
Metabolic alkalosis or acidosis
Notably, accumulation of citrate can additionally lead to 
acid–base derangements. Metabolic alkalosis occurs if a 
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or accidentally rapid infusion) is delivered and when the 
citrate is appropriately metabolized, providing bicar  bo-
nate equivalents or, according to the Stewart concept, 
leaving unopposed sodium (see above) [38]. Metabolic 
acidosis occurs if a large citrate dose is not metabolized; 
for example, in liver failure or poor peripheral perfusion. 
A high lactate level (for example, >5 mmol/l) in patients 
with liver failure before the start of citrate CRRT may act 
as a useful marker of greater risk for citrate accumulation. 
Septic patients with a high lactate level generally tolerate 
citrate remarkably well if circulation improves. Accumu-
lation of citrate is easily detectable with standard mon  i-
tor  ing: arterial blood gases, ionized and total calcium at 
6-hour intervals. If citrate accumulation occurs together 
with metabolic acidosis and an increasing calcium ratio, 
the citrate dose should be decreased or discontinued, 
calcium replaced and the patient should receive bicar-
bonate replacement, preferably as part of the balanced 
replacement ﬂ  uids [38]. With proper monitoring, citrate 
accumulation causes no clinical symptoms.
Infl  ammation
Apart from the potentially proinﬂ  ammatory  eﬀ  ects  of 
heparin on the release of mediators from leukocytes and 
platelets (see above), it may be hypothesized that local 
hypocalcemia at a membrane level during anticoagulation 
with citrate might reduce inﬂ  ammatory mediator release 
from cells adhered to the membrane [46,47]. Activation 
of neutrophils and the release of mediators from intra-
cellular granules are preceded by transient increases in 
cytosolic Ca2+ caused by the mobilization of Ca2+ from 
intracellular stores followed by the inﬂ  ux of Ca2+ into the 
cell through the plasma membrane channels. Cytosolic 
Ca2+ subsequently acts as an intracellular messenger 
[48-50]. It should be noted that the eﬀ  ects of citrate on 
complement activation, especially seen when using the 
old unsubstituted cuprophane membranes, are not 
uniform – some studies report no eﬀ  ect [51-53], others 
report a suppression of activation [46]. Degranulation 
seems to be mediated by a diﬀ  erent membrane receptor, 
not related to complement activation and neutropenia 
[54].
Energy and mitochondria
Citrate (C6H5O7) is a source of energy, conferring 3 kcal/g 
(0.59 kcal/mmol) [55,56]. One gram of citrate corres-
ponds to about 5 mmol. Part of the citrate administered 
before the ﬁ   lter enters the patient’s circulation. Th  e 
amount depends on the citrate infusion dose, its 
concentration in the ﬁ  lter and the amount removed by 
ﬁ  ltration or dialysis. Th   e latter can be estimated, because 
the sieving coeﬃ   cient of citrate is close to 1.0. Eﬄ   uent 
loss corresponds to eﬄ   uent ﬂ  ow × citrate concentration 
in the ﬁ  lter. Th   e citrate concentration in the ﬁ  lter can be 
estimated by dividing the administered amount by blood 
ﬂ  ow. Postdilution hemoﬁ  ltration estimation is easiest – 
the amount lost by ﬁ  ltration equals the infusion rate × 
ﬁ  ltration fraction, and the amount entering the patient is 
equivalent to the infusion rate × (1 – ﬁ  ltration fraction). 
Assuming a blood ﬂ   ow of 200 ml/minute, a citrate 
infusion rate of 3 mmol/l blood ﬂ  ow (36 mmol/hour), a 
ﬁ  ltration fraction of 0.20, and a ﬁ  lter running 80% of the 
time, about 553 mmol citrate enter the patient’s circu-
lation per day, providing close to 333 kcal/day. Th  e 
present calculation is an estimate, based on physiological 
principles. Actual measurements have been published in 
abstract form recently [57].
Note that citrate, although being an energy source, 
does not need insulin to enter the cell. Citrate is an easy 
fuel for the mitochondria, and may replenish the Krebs 
cycle if intermediates are scarce. Substrate availability is a 
crucial regulator of the Krebs cycle. Th   e cycle is a central 
pathway providing energy and maintaining the mito-
chon  drial redox state. In sepsis, inhibition of pyruvate 
dehydrogenase limits pyruvate conversion to acetyl-
coenzyme A, the main substrate of the cycle [58]. 
Further  more, Weinberg and colleagues have shown that 
citric acid cycle intermediates may protect proximal 
tubules against injury and may promote recovery from 
sustained mitochondrial energetic deﬁ  cit.  Th  is deﬁ  cit 
occurs after hypoxia and reperfusion and acts by 
lowering the cellular burden of non-esteriﬁ  ed fatty acids 
that appear to account for much of the continuing mito-
chondrial dysfunction [59,60]. Th   e serum concentrations 
of citrate reached during CRRT with citrate as an 
anticoagulant (0.3 to 0.5 mmol/l) [44] are in the range 
expected to modify tubular cell metabolism (personal 
communication).
Life-threatening adverse event
Th  e main risk of citrate anticoagulation consists of the 
uncontrolled systemic infusion of a hypertonic citrate 
solution causing acute and severe hypocalcemia, hypo-
tension and possibly cardiac arrest. Treatment consists of 
immediate calcium infusion and discontinuation of 
citrate infusion.
Costs
Although comparative studies are not available and 
expenses diﬀ  er between modalities, estimated costs of 
citrate anticoagulation are not substantially higher than 
those associated with heparin anticoagulation. Instead of 
measuring the activated partial thromboplastin time for 
the control of heparin anticoagulation, systemic ionized 
calcium and once-daily measurement of total calcium is 
suﬃ   cient for the monitoring citrate accumulation, with 
more frequent measurement only in patients at risk of 
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calcium are slightly more expensive when citrate is used. 
If the costs of less bleeding and longer circuit life are 
calculated, costs with citrate are probably less or may in 
fact represent cost savings.
Strategies to increase the safety of citrate
Th   e use of citrate oﬀ  ers many advantages to the patient, 
which can only be taken if the risks are well controlled. 
Th   e incidence of metabolic complications largely 
depends on the design, rules and ﬂ   exibility of the 
protocol, and its proper use. Safe introduction of citrate 
should start with the choice of a well-designed and 
ﬂ  exible protocol with proven eﬃ   cacy and adjusted to the 
local preferences of modality and dose, and availability of 
ﬂ  uids and devices. Results of ionized calcium measure-
ment should be available 24 hours a day. Implementation 
of the protocol includes the training of staﬀ   to create 
understanding and awareness of acid–base and calcium 
monitoring, and the correction of imbalance [38]. Safety 
is further improved by the incorporation of a citrate 
module in the CRRT device, blocking persistent citrate 
infusion if the blood pump stops. Pop-ups in the patient 
data management system and computerized algorithms 
may add to patient safety.
Heparin versus citrate: randomized controlled 
trials
Effi   cacy and side eff  ects
Th  e primary goal of anticoagulation for CRRT is to 
extend circuit life. Indeed, a shorter circuit life may result 
in underdosing of CRRT. Several studies have compared 
circuit life and bleeding complications under citrate 
treatment with nonrandomized controls on heparin 
treat  ment (summarized in [13,38]). Groups were often 
not comparable, because the patients receiving citrate 
generally had a higher bleeding risk. Nevertheless, 
bleeding complica  tions were lower in patients receiving 
citrate [61,62]. Circuit survival with citrate was usually 
longer, some  times similar and, in some studies, shorter 
than with heparin (summarized in [38]). Five randomized 
con  trolled studies comparing anticoagulation with citrate 
to anticoagulation with heparin have been published 
[63-66] (Table 1). Th  ree of these studies report a 
signiﬁ   cantly longer circuit survival with citrate, four 
studies (a trend to) less bleed  ing, and two studies less red 
blood cell transfusion using citrate.
Clinical outcomes
Most randomized studies evaluating heparin anticoagu-
lation for CRRT are too small for a robust evaluation of 
clinical outcome [13]. A recent randomized study in 200 
critically ill patients receiving CRRT for acute kidney 
injury, comparing anticoagulation with LMWH (nadro-
parin) to regional anticoagulation with citrate, un-
expectedly showed a 15% absolute increase in 3-month 
survival using an intention-to-treat analysis [35] (Table 2). 
In addition to improved patient survival, kidney survival 
was also better with citrate. Th  e  diﬀ  erence was signiﬁ  cant 
for all per-protocol patients and tended to signiﬁ  cance 
for the sur  viving patients. Among the higher proportion 
of surviving patients, therefore, more patients were free 
from chronic dialysis in the citrate group. Of note, the 
beneﬁ  t of citrate on survival could not be fully explained 
by less bleeding. Citrate appeared particularly beneﬁ  cial 
in surgical patients, younger patients, patients with sepsis 
(compared with no sepsis) and in patients with a high 
degree of organ failure. In none of the subgroups did 
citrate perform worse than heparin. Th  ese ﬁ  ndings 
suggest the need for a better understanding of citrate 
Table 1. Randomized clinical studies comparing citrate with heparin anticoagulation for CRRT
  Circuit life (hours)a  Bleeding Transfusion  (RBC/dayb) Survival
Reference  Design  Citrate Heparin Citrate Heparin Citrate Heparin Citrate Heparin
Monchi and   RCOT,   70   40  n = 0  n = 1  0.2   1.0   
colleagues [63]  n = 20  (44 to 140),  (17 to 48)      (0 to 0.4),  (0 to 2.0)
   P <0.001      P <0.001    
Kutsogiannis and   RCT,   125   38  RR 0.17    0.53      
colleagues [64]  n = 30  (95 to 157),  (25 to 62)  (0.03 to 1.04),     (0.24 to 1.20),     
   P <0.001  P = 0.06    P = 0.13     
Betjes and   RCT,       0%,   33%  0.43,   0.88   
colleagues [65]  n = 48      P <0.01    P = 0.01     
Oudemans-Van   RCTc,   27   26  6%,   16%  0.27    0.36  52%d,   37%d
Straaten and  n = 200  (13 to 47),  (15 to 43)  P = 0.08    (0 to 0.63),  (0 to 0.83)  P = 0.03
colleagues  [35]   NS       P = 0.31     
Hetzel and   RCT,   37.5 ± 23,   26.1 ± 19.2  14.5%,   5.7%      ±30%e,   ±43%e
colleagues [66]  n = 170  P <0.001  P =  0.06      NS 
CRRT, continuous renal replacement therapy; RCOT, randomized cross-over trial; RCT, randomized controlled trial; NS, not signifi  cant; RR, relative risk. aMedian 
(interquartile range). bNumber of red cell units per day of continuous venovenous hemofi  ltration. cComparing citrate with the low molecular weight heparin 
nadroparin. dThree-month survival on an intention-to-treat analysis. eThirty-day mortality, estimated from the Kaplan–Meier curve.
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however, were not conﬁ  rmed in a more recent multi-
center randomized trial, including a slightly diﬀ  erent 
patient population, using a diﬀ  erent citrate protocol and 
reporting a shorter follow-up [66].
Conclusion
Th  e use of heparin as an anticoagulant for CRRT is 
hampered by complex interactions between the drug and 
numerous acute phase proteins, and apoptotic and 
necrotic cells. In addition, heparin binding inhibits the 
anti-inﬂ  ammatory eﬀ  ects of AT, which may already be 
low, and triggers the release of inﬂ  ammatory mediators 
from blood and endothelial cells. Th   is myriad of actions 
leads to an unpredictable dose–eﬀ  ect relationship and an 
uncontrollable and potentially deleterious interference 
with proinﬂ  ammatory and anti-inﬂ  ammatory pathways. 
In randomized clinical trials, heparins are often less 
eﬀ  ective for preserving circuit life while they increase the 
patient’s risk of bleeding. Th  e  beneﬁ  ts of citrate include 
less bleeding, a longer or similar circuit life, and possibly 
better patient and kidney survival. Th   e last beneﬁ  t needs 
to be conﬁ  rmed in larger randomized controlled multi-
center trials. Th   e use of citrate might be associated with 
less inﬂ  ammation and has useful bio-energetic implica-
tions. Th   ese observations call into question the primacy 
of heparins for circuit anticoagulation in the critically ill 
patient and suggest a greater role for citrate (Table 2). 
Table 2. Advantages and disadvantages of heparin or citrate anticoagulation during continuous renal replacement 
therapy
   Heparins  Citrate
Clinical  
  Anticoagulation  Regional and systemic  Regional, not systemic
  Risk of bleeding  Higher  Not increased
  Circuit life  Similar or shorter  Similar or longer
  Metabolic control  Good  Good if well performed
  Metabolic derangements    Greater risk if not well controlled
 Understanding  Easy  Diffi   cult
  Life-threatening complications  Massive bleeding 
    Heparin-induced thrombocytopenia (UFH >LMWH)  Cardiac arrest due to unintended rapid infusion
  Clinical outcome    Possibly better patient and kidney survival
Biochemical  
  Anticoagulation  Critically ill patients exhibit heparin resistance due to: 
    •  Low antithrombin (high consumption and degradation) 
    •  Acute phase proteins and apoptotic/necrotic cells bind 
       heparin (UFH >LMWH) 
 Proinfl   ammatory  eff  ects  Inhibit the anti-infl  ammatory properties of antithrombin 
   (UFH  >LMWH) 
    Trigger antithrombin degradation by elastase 
    Release myeloperoxidase, elastase, platelet factor 4, 
    superoxide dismutase into the circulation (UFH, LMWH) 
    Increase in lipopolysaccharide-induced, LPB-dependent 
    IL-8 and IL-1β secretion from monocytes (LMWH, UFH) 
 Anti-infl   ammatory  eff  ects  Inhibit thrombin generation (UFH, LMWH)  Its use prevents the release of granular products from 
      neutrophils and platelets
    Block P-selectin and L selectin-mediated cell adhesion 
   (UFH,  LMWH) 
    Decrease cytokine generation in vitro, not in vivo 
  Phagocytosis  Bind to apoptotic and necrotic cells and may delay 
    phagocytic clearance (UFH >LMWH) 
  Bio-energetic properties    Provides energy without needing insulin for entrance into 
     the  cell
      May protect against mitochondrial dysfunction
UFH, unfractionated heparin; LMWH, low molecular weight heparin; LBP, lipopolysaccharide-binding protein.
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Page 7 of 9Th   e full advantage of citrate anticoagulation can only be 
realized, however, if its risks are well controlled by means 
of a sound protocol, well-trained staﬀ  , and the incor-
poration of a citrate module in the CRRT device.
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